Fri, Sep 19, 2014, 12:50 AM EDT - U.S. Markets open in 8 hrs 40 mins


% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

factman777 16 posts  |  Last Activity: Sep 12, 2014 3:22 PM Member since: Oct 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • factman777 factman777 Sep 12, 2014 3:22 PM Flag

    The exercise of the warrants would extend the cash runway into 2017. Of course, the stock has to get above $1.43 for this to happen. Enrolling the first patient should do the trick.

    Sentiment: Strong Buy

  • factman777 by factman777 Sep 10, 2014 5:07 PM Flag

    Does anyone know how to get YAHOO Finance to pick this up article so it appears under Headlines?

    Sentiment: Strong Buy

  • Reply to

    "New" Investor presentation posted

    by alleg180 Sep 8, 2014 9:23 AM
    factman777 factman777 Sep 8, 2014 10:09 AM Flag

    They also added under:: Human pilot study on page 23

    the following:

    After 2 patients have been safely treated, InVivo plans to approach FDA about removing 3 month hold between patients

    Sentiment: Strong Buy

  • You seem to be the most informed and level headed poster on this board.

    What is your opinion on the total lack of insider buying? Do you think it is possible that since the Annual Shareholders meeting on July 30 that the company has been in a quiet period where insider buying is not permitted? I was at this meeting and McCarthy said the windows for insider buying have been small with all that had been going in with the company but the window for buying shares on the open market should be much larger going forward.

    Also, I believe a company should only reverse split their stock to maintain a listing on an exchange. Since NVIV is on the OTCBB there is no need to. Reverse splits almost always hurts shareholder value, especially with a company that has no revenues. Can you see a scenario why management would do a reverse split?

    Sentiment: Strong Buy

  • Reply to

    somethings gotta give....

    by flsh56 Sep 4, 2014 11:24 AM
    factman777 factman777 Sep 4, 2014 3:58 PM Flag

    No way they announce a reverse split now. Not for a company with no revenues. Reverse splits almost always hurts shareholder value. The only time a company should consider reverse splitting their stock is to maintain a listing on an exchange. They are on the OTCBB and do not need to reverse split their stock to stay on the OTCBB.

    Sentiment: Strong Buy

  • Reply to

    Question on SC 13D/A filed on Aug 29, 2014

    by factman777 Sep 4, 2014 3:44 PM
    factman777 factman777 Sep 4, 2014 3:49 PM Flag

    Answered my own question. The Schedule 13D states the following:

    The aggregate number of shares of Common Stock beneficially owned by the Reporting Persons is 6,945,699 as of the date of this Amendment No. 3. The aggregate number of shares of Common Stock beneficially owned by the Reporting Person represents a 7.4% ownership interest of the Company.

    Sentiment: Strong Buy

  • The Schedule 13D has Aug 7, 2014 as the “Date of Event which Requires Filing of this Statement”

    It states the Aggregate amount beneficially owned by each reporting person = 6,945,699.

    It also states from 8/8/2014 to 8/28/201 1,507,409 shares were sold by Frank.

    Does he have the following shares left: 6,945,699 - 1,507,409 = 5,438,290 ?
    Or does the 6,945,699.indicate the amount owned at the time of the filing?

    He originally acquired 15,147,600 shares on Oct 26, 2010.

    Sentiment: Strong Buy

  • First let me state that I am not a tax expert.

    Here is something that may be worth doing if you are holding you InVivo shares in a Tradiional IRA. Since the price is so low you may want to covert to a Roth IRA. Then if InVivo goes back up, you do not have to pay taxes on the gains when you withdraw at age 59 ½ or older. However, you will have to pay tax on the conversion amount for the tax year 2014. The good thing about this strategy is that if InVivo declines further you have until Oct 15, 2015 to undo the conversion which is called: re-characterization. If you undo the conversion then you do not have to pay taxes. It’s like you never converted in the first place. You then need to wait 30 days and then you can convert again if you wish.

    So let’s say you own 100,000 shares of InVivo. Your convert 33,000 shares at $0.63. You will have to pax taxes on $20,790. InVivo then drops to $0.50. You re-characterize the 33,000 shares. From the other 67,000 shares you then immediately convert 33,000 shares to a new Roth IRA at $0.50. Now you have to pay taxes only on the new conversion which is $16,500. The original conversion at $0.63 never happened. You have to make sure you keep each Roth conversion in its own new Roth IRA account so as to keep track of which shares can be re-characterize and if you have to wait 30 days to convert more shares after a re-characterization. My scenario describes the beginnings of how you could reduce the tax hit if InVivo falls further after conversion(s).

    Of course, you could convert all 100,000 shares and if InVivo goes up and you can handle the tax hit on $63,000 then you are good to go. If InVivo then went down you could re-characterize the100,000 shares. But then you have to wait 30 days to convert again and it could be just you luck that within those 30 days the first patient is enrolled and gets up and walks!
    Please Google: “Fidelity How to reverse a Roth IRA conversion” for more information on recharacteri

    Sentiment: Strong Buy

  • factman777 factman777 Aug 7, 2014 2:55 AM Flag

    If the first patient regains some function (without stem cells) this is going over $10 in a hurry.

    Sentiment: Strong Buy

  • factman777 factman777 Aug 6, 2014 8:36 PM Flag

    The Company's transactions in InVivo securities during the Class Period were as follows:
    6/13/2013 BUY 2,000 shares at $3.85.

    A 2,000 share transaction, please!!!

    Pretty savvy shareholders we have out there, NOT. The stock dropped 10% over nothing.
    The smart money is buying and these fire sale prices will not last much longer. The company will have cash out to early 2017 after the 7 million warrants are exercised. Folks, that over 2 1/2 years. A lot can happen in 2 1/2 years.

    -No BS, Just the facts,

    Sentiment: Strong Buy

  • factman777 factman777 Aug 6, 2014 8:11 PM Flag

    And if they execute the 7 million warrants at $1.43 then that will bring in another 10 million dollars so they should be good for the next 2 1/2 years or until early 2017.

    Sentiment: Strong Buy

  • factman777 by factman777 Jul 31, 2014 12:38 AM Flag

    I also attended the meeting. Here are my bullets…

    -Frank and one other shareholder voted shares in person at the meeting. Frank asked for a count and management told him to check the SEC site.
    -As others reported, Frank left the Q&A session early after questions about Hydrogel and the secondary offering price. It was quite obvious that Frank and McCarthy are not the best of friends.
    -The tension significantly dropped in the room after Frank left with two other people that had accompanied him. My guess was one of them was a lawyer.
    -The 7 million warrant conversion at $1.43 should provide the company cash into 2017.
    -Perrin repeated several times that the timing of the first patient is out of the company’s control which makes sense to me.
    -Additional 3 sites (not in MA) will be up by Sept 30, 2014 and Perrin said that they would be impressive.
    -Perrin said they are going to significantly step up IR/PR efforts and are looking into hiring an IR firm.
    -Question on the total lack of insider buying by the BOD was asked and several on the board seem more receptive to making purchases in the future. McCarthy said the windows for insider buying have been small with all that has been going in with the company but the window will be much larger going forward.
    -Tom Ulich, the Chief Scientific Officer, did a nice job presented the medical sections of the slides and answering questions during the Q&A period.
    -I myself was more impressed with Perrin then I thought I would be and there was a genuine excitement by the Invivo management. They seem to have their act together. Now all we need is the 1st patient to enroll which we should all understand is out of the company's control.

  • factman777 factman777 Jun 24, 2014 5:29 PM Flag

    Looks like MR. Perrin is also recognizing the hard work as Mr. Astrue did. The January 1, 2014 press release stated the following:

    "InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.

    Interim Chief Executive Officer Michael Astrue said, “These two executives have been instrumental in our effort to put our first product candidate into the clinic in the next few months. They have both also demonstrated expertise and judgment with their work on InVivo’s evolving pipeline.”

    Sentiment: Strong Buy

  • It would take another company a decade and a ton of R&D money to get to where InVivo is today. Think about all the animal studies that have to be performed and even more difficult to get the Human clinical trials approved by our snail-moving FDA. So why are we selling for $1.01? Simple... its because of the replacement of the former CEO (who told several lies by omission) and some typical delays when doing business in the bio-tech field. Delays in the bio-tech field are part of the norm but they provide the bashes with ample ammunition to drive a stock price down.

    However, everything is now in place. All systems are now a go with plenty of cash to see the human clinical trials through.

    By the way: Lying by omission is when an important fact is omitted, deliberately leaving another person with a misconception. This includes failures to correct pre-existing misconceptions. Frank Reynolds was very good at lying by omission and misleading the shareholders.

    Michael Astrue,a man of high integrity who turned around InVivo and told the shareholders the truth, handpicked Mark Perrin to be the new CEO so I am confident going forward. Mr. Astrue also took his outgoing bonus in shares of InVivo instead of cash.

    The more I think about it the more I like the risk/reward going forward...

    Sentiment: Strong Buy

  • It was obvious that the Hydrogel platform was another pipe dream from the former CEO Frank Reynolds. That why the Investor Relation presentation from May 2, 2014 had only 3 of the 51 pages about Hydrogel. (Note: the presentation has been updated as of today). The company is now laser focused on the Neuro-Spinal Scaffold human clinical trials which can enroll their first patient anytime now and the company now has existing funds through March 2016. Also, the 7 million warrants at $1.43 that will bring in an additional $10 million dollars down the road.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    I like the risk/reward going forward…

    Sentiment: Strong Buy

  • I left a message yesterday and he called me back this morning.

    He only provides information that is already public which is of course is what he is supposed to do. However, he did say that they have used Root Cause Analysis (RCA) to identify the manufacturing issues with respect to the scaffold and that they are very confident that they will be enrolling subjects in the second quarter of 2014.

    From Wikipedia…

    Root cause analysis (RCA) is a method of problem solving that tries to identify the root causes of faults or problems. RCA practice tries to solve problems by attempting to identify and correct the root causes of events, as opposed to simply addressing their symptoms. Focusing correction on root causes has the goal of preventing problem recurrence.

    Sentiment: Strong Buy

0.50-0.02(-3.85%)Sep 18 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT